SCEMBLIX was studied vs all* standard-of-care TKIs in patients with newly diagnosed Ph+ CML-CP in ASC4FIRST^2,4,†

*Imatinib, nilotinib, dasatinib, and bosutinib.

Superior response rates vs IS-TKIs²

^‡IS-TKIs included imatinib (400 mg once daily) and other TKIs of nilotinib (300 mg twice daily), dasatinib (100 mg once daily), or bosutinib (400 mg once daily).

Safety and tolerability profile^2,5

AR, adverse reaction; ELTS, EUTOS long-term survival; EUTOS, EUropean Treatment Outcome Study; IS-TKI, Investigator-selected tyrosine kinase inhibitor; MMR, major molecular response; NCCN, National Comprehensive Cancer Network; qd, once daily; TKI, tyrosine kinase inhibitor.

^†ASC4FIRST is a multicenter, randomized, active-controlled, open-label study of 405 adults with newly diagnosed Ph+ CML-CP. Investigators, in consultation with patients, preselected the appropriate TKI and evaluated ELTS risk scores. Patients were then stratified by TKI and ELTS score, then randomized (1:1) to receive either SCEMBLIX or an Investigator-selected TKI (imatinib, nilotinib, bosutinib, or dasatinib). 201 patients received SCEMBLIX at 80 mg qd, and 204 patients received IS-TKIs until unacceptable toxicity or treatment failure occurred.^2,4